secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001193125-24-001884
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera unveils STAT6 degrader KT-621 (Phase 1 in H2 2024) and TYK2 degrader KT-294 (Phase 1 in H1 2025)
--------------------------------------------------------------------------------

- KT-621 (STAT6 degrader) expected to enter Phase 1 in H2 2024; preclinical data shows superior efficacy to dupilumab.
- KT-294 (TYK2 degrader) planned to enter Phase 1 in H1 2025; potential to recapitulate TYK2 loss-of-function biology.
- KT-474 (IRAK4 degrader) Phase 2 enrollment in HS and AD expected to complete Q4 2024; topline data H1 2025.
- Both KT-621 and KT-294 are wholly-owned, once-daily oral degraders targeting validated autoimmune pathways.
- Company holds virtual R&D Day on Jan 4, 2024 to present immunology strategy and new preclinical data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524001884/0001193125-24-001884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524001884/d378650d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-001884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer